13
views
0
recommends
+1 Recommend
0 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: found
      Is Open Access

      Evaluation of DOAC Dipstick Test for Detecting Direct Oral Anticoagulants in Urine Compared with a Clinically Relevant Plasma Threshold Concentration

      research-article

      Read this article at

      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          Measuring direct oral anticoagulant (DOAC) concentrations might be necessary in certain clinical situations but is not routinely performed. The DOAC Dipstick is a new rapid test for detecting DOACs in urine. The aim of this study was to evaluate the possible uses and limitations of the DOAC Dipstick and to compare visual analysis and DOASENSE Reader analysis of DOAC Dipstick pads. Plasma and urine samples were collected from 23 patients taking DOACs. DOAC concentrations in plasma and urine were measured by chromogenic substrate assays and in urine also by the DOAC Dipstick. Plasma concentrations were dichotomized at a threshold of ≥30 ng/mL. Patient samples were compared with samples from control individuals not using anticoagulants (n = 10) and with DOASENSE control urines. The Combur-10 test was used to measure parameters that may affect urine color and hence the interpretation of the DOAC Dipstick result. DOAC Dipstick test results were positive in 21/23 patient urine samples at a plasma DOAC concentration of ≥30 ng/mL and in 2/23 patient urine samples at a plasma DOAC concentration of <30 ng/mL. Inter-observer agreement was above 90% for visual analysis of patient urine samples and was 100% for DOASENSE Reader analysis of patient urines and for analysis of control group urines and DOASENSE control urines. Abnormalities in urine color detected by the Combur-10 test did not affect the DOAC Dipstick results. DOAC Dipstick detects DOACs in urine at a plasma threshold of ≥30 ng/mL. Positive DOAC Dipstick results should be confirmed by measuring DOAC plasma concentration.

          Related collections

          Most cited references12

          • Record: found
          • Abstract: found
          • Article: not found

          Laboratory testing in patients treated with direct oral anticoagulants: a practical guide for clinicians

          Click to hear Dr Baglin's perspective on the role of the laboratory in treatment with new oral anticoagulants SUMMARY: One of the key benefits of the direct oral anticoagulants (DOACs) is that they do not require routine laboratory monitoring. Nevertheless, assessment of DOAC exposure and anticoagulant effects may become useful in various clinical scenarios. The five approved DOACs (apixaban, betrixaban, dabigatran etexilate, edoxaban and rivaroxaban) have different characteristics impacting assay selection and the interpretation of results. This article provides an updated overview on (i) which test to use (and their advantages and limitations), (ii) when to assay DOAC levels, (iii) how to interpret the results relating to bleeding risk, emergency situations and perioperative management, and (iv) what is the impact of DOACs on routine and specialized coagulation assays. Assays for anti-Xa or anti-IIa activity are the preferred methods when quantitative information is useful, although the situations in which to test for DOAC levels are still debated. Different reagent sensitivities and variabilities in laboratory calibrations impact assay results. International calibration standards for all specific tests for each DOAC are needed to reduce the inter-laboratory variability and allow inter-study comparisons. The impact of the DOACs on hemostasis testing may cause false-positive or false-negative results; however, these can be minimized by using specific assays and collecting blood samples at trough concentrations. Finally, prospective clinical trials are needed to validate the safety and efficacy of proposed laboratory thresholds in relation to clinical decisions. We offer recommendations on the tests to use for measuring DOACs and practical guidance on laboratory testing to help patient management and avoid diagnostic errors.
            Bookmark
            • Record: found
            • Abstract: found
            • Article: not found

            2021 Update of the International Council for Standardization in Haematology Recommendations for Laboratory Measurement of Direct Oral Anticoagulants.

            In 2018, the International Council for Standardization in Haematology (ICSH) published a consensus document providing guidance for laboratories on measuring direct oral anticoagulants (DOACs). Since that publication, several significant changes related to DOACs have occurred, including the approval of a new DOAC by the Food and Drug Administration, betrixaban, and a specific DOAC reversal agent intended for use when the reversal of anticoagulation with apixaban or rivaroxaban is needed due to life-threatening or uncontrolled bleeding, andexanet alfa. In addition, this ICSH Working Party recognized areas where additional information was warranted, including patient population considerations and updates in point-of-care testing. The information in this manuscript supplements our previous ICSH DOAC laboratory guidance document. The recommendations provided are based on (1) information from peer-reviewed publications about laboratory measurement of DOACs, (2) contributing author's personal experience/expert opinion and (3) good laboratory practice.
              Bookmark
              • Record: found
              • Abstract: found
              • Article: not found

              Evaluation of coagulation assays versus LC-MS/MS for determinations of dabigatran concentrations in plasma.

              Dabigatran is an oral direct thrombin inhibitor for which routine laboratory monitoring is currently not recommended. However, there are situations in which measurements of the drug and its effect are desirable. We therefore compared and validated different coagulation methods for assessments of dabigatran in clinical samples in relation to measurements of plasma dabigatran, without the purpose of establishing effective and safe concentrations of dabigatran in plasma.
                Bookmark

                Author and article information

                Journal
                Clin Appl Thromb Hemost
                Clin Appl Thromb Hemost
                CAT
                spcat
                Clinical and Applied Thrombosis/Hemostasis
                SAGE Publications (Sage CA: Los Angeles, CA )
                1076-0296
                1938-2723
                7 March 2022
                Jan-Dec 2022
                : 28
                : 10760296221084307
                Affiliations
                [1 ]Department of Emergency Medicine, Ringgold 91887, universityNorth Estonia Medical Centre; , Tallinn, Estonia
                [2 ]Institute of Clinical Medicine, Faculty of Medicine, Ringgold 37546, universityUniversity of Tartu; , Tartu, Estonia
                [3 ]Centre of Cardiology, Ringgold 91887, universityNorth Estonia Medical Centre; , Tallinn, Estonia
                [4 ]Department of Cardiology, Ringgold 37546, universityUniversity of Tartu; , Tartu, Estonia
                [5 ]Department of Internal Medicine, Ringgold 91887, universityNorth Estonia Medical Centre; , Tallinn, Estonia
                [6 ]Department of Physiology, Biochemistry, Microbiology and Laboratory Medicine, Institute of Biomedical Sciences, Faculty of Medicine, Ringgold 54694, universityVilnius University; , Vilnius, Lithuania
                [7 ]Ringgold 612304, universityMediq Eesti OÜ; , Tallinn, Estonia
                [8 ]Department of Laboratory Medicine, Ringgold 91887, universityNorth Estonia Medical Centre; , Tallinn, Estonia
                [9 ]Department of Health Technologies, Ringgold 54561, universityTallinn University of Technology; , Tallinn, Estonia
                Author notes
                [*]Marika Pikta, MD, Department of Laboratory Medicine, North Estonia Medical Centre, 19 J. Sütiste Str, 13419 Tallinn, Estonia. Email: marika.pikta@ 123456regionaalhaigla.ee
                Author information
                https://orcid.org/0000-0002-5891-7589
                Article
                10.1177_10760296221084307
                10.1177/10760296221084307
                8905053
                35249379
                439dedd0-9743-4e78-97d7-66d28cd55a06
                © The Author(s) 2022

                This article is distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 License ( https://creativecommons.org/licenses/by-nc/4.0/) which permits non-commercial use, reproduction and distribution of the work without further permission provided the original work is attributed as specified on the SAGE and Open Access page ( https://us.sagepub.com/en-us/nam/open-access-at-sage).

                History
                : 21 December 2021
                : 8 February 2022
                : 11 February 2022
                Categories
                Original Manuscript
                Custom metadata
                ts19
                January-December 2022

                apixaban,dabigatran,direct oral anticoagulants,edoxaban,rivaroxaban

                Comments

                Comment on this article